Trial By Fire Solutions Offers Expanded Clinical Study Management Capabilities With New Release of SimpleCTMS
Trial By Fire Solutions announced the general release of SimpleCTMS, a software solution designed to optimize clinical study management costs and improve clinical trial management efficiencies.
The latest release follows a successful 6-month pilot program where the software was put to practice by drug developers and clinical research organizations. Based on collaborative feedback with pilot program participants, a number of new enhancements have been incorporated which add to the functionality of SimpleCTMS. The Trial By Fire Solutions team will roll-out additional SimpleCTMS features in 2011.
SimpleCTMS was designed and developed to offer the benefits of a CTMS (Clinical Trial Management System) without the extensive upfront financial and resource commitments associated with traditional enterprise systems or the inherent inefficiencies of worksheet trackers. SimpleCTMS provides early stage drug developers a scalable and cost effective solution to improve the management, performance and study startup costs associated with clinical trials.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
